Top

Published in:

01-02-2010 | Clinical Study - Patient Study

Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker

Authors: Rajan Jain, Lisa M. Scarpace, Shehanaz Ellika, Roy Torcuator, Lonni R. Schultz, David Hearshen, Tom Mikkelsen

Published in: Journal of Neuro-Oncology | Issue 3/2010

Abstract

The purpose of this study was to assess the usefulness of diffusion weighted imaging as an additional imaging biomarker for treatment response in recurrent/progressive malignant gliomas treated with bevacizumab alone or in combination with other chemotherapeutic agents. Twenty patients treated with bevacizumab alone or concurrent chemotherapy were followed up with serial MR imaging. Volume and ADC values of contrast enhancing lesion (CEL_vol, CEL_ADC) and also of non-enhancing lesion (NEL_vol, NEL_ADC) were obtained. CEL_vol showed a progressive decrease in non-progressors with a median percentage change of −73.2% (P = 0.001) as compared to −33.4% for progressors by 1 year/last imaging (P = 0.382). NEL_vol also showed a decrease in non-progressors on follow up imaging though only significant for 3 months follow up (P = 0.042). In progressors, CEL_vol and NEL_vol showed initial decrease followed by slight increase by 1 year/last imaging though not significant (P value of 0.382 and 0.46, respectively). CEL_ADC and NEL_ADC in non-progressors did not show any statistically significant change though there was slight trend for positive percent change especially for CEL_ADC by 1 year/last imaging follow up study (P value of 0.077 and 0.339, respectively). Progressors showed a progressive negative percent change of CEL_ADC and NEL_ADC. In progressors, NEL_ADC decreased at 6 weeks (P = 0.054), 3 months (P = 0.023) and 1 year/last (P = 0.078) as compared to baseline study and was also statistically significant as compared to non-progressors at 6 weeks (P = 0.047) and 3 months (P = 0.025). CEL_ADC and NEL_ADC appear to follow different trends over time for non-progressors and progressors with a stable to slightly progressive increase in non-progressors and a progressive decrease in progressors, especially early on. These findings suggest that DWI may be used as an additional imaging biomarker for early treatment response.

Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207–214CrossRefPubMed

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed

Macdonald DR, Cascino TL, Schold SC et al (1990) Response criteria for phase II studies of malignant glioma. J Clin Oncol 8:1277–1280PubMed

Henson JW, Ulmer S, Harris GJ (2008) Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 29(3):419–424CrossRefPubMed

Sorensen AG, Batchelor TT, Wen PY et al (2008) Response criteria for glioma. Nat Clin Pract Oncol 5:634–644CrossRefPubMed

Le Bihan D, Breton E, Lallemand D et al (1986) MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 161:401–407PubMed

Tien RD, Felsberg GJ, Friedman H et al (1994) MR imaging of high-grade cerebral gliomas: value of diffusion weighted echoplanar pulse sequences. AJR Am J Roentgenol 162:671–677PubMed

Brunberg JA, Chenevert TL, McKeever PE et al (1995) In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres. AJNR Am J Neuroradiol 16:361–371PubMed

Noguchi K, Watanabe N, Nagayoshi T et al (1999) Role of diffusion weighted echo-planar MRI in distinguishing between brain abscess and tumor: a preliminary report. Neuroradiology 41:171–174CrossRefPubMed

10.

Gupta RK, Sinha U, Cloughesy TF et al (1999) Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. Magn Reson Med 41:2–7CrossRefPubMed

11.

Stark Vance V (2005) Bevacizumab (Avastin) and CPT-11 (Camptosar) in the treatment of relapsed malignant glioma. Neurooncology 7:369

12.

Pope WB, Lai A, Nghiemphu P et al (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66:1258–1260CrossRefPubMed

13.

Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant glioma. Clin Cancer Res 13:1253–1259CrossRefPubMed

14.

Holash J, Maisonpierre PC, Compton D et al (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994–1998CrossRefPubMed

15.

Kunkel P, Ulbricht U, Bohlen O et al (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61:6624–6628PubMed

16.

Rubenstein JL, Kim J, Ozawa T et al (2000) Anti-VEGF antibody treatment for glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306–314CrossRefPubMed

17.

Norden AD, Young GS, Setayesh K (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70(10):779–787CrossRefPubMed

18.

Fischer I, Cunliffe CH, Bollo RJ (2008) High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neurooncology 10(5):700–708

19.

Batchelor TT, Sorensen AG et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95CrossRefPubMed

20.

Moffat BA, Chenevert TL, Meyer CR et al (2006) The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 8:259–267CrossRefPubMed

21.

Ellika S, Jain R, Scarpace L, et al. (2007) Role of functional diffusion maps in predicting progression of low grade gliomas. In: Proceedings of American society of neuroradiology annual meeting 2007, p 242

22.

Ananthnarayan S, Bahng J, Roring J et al (2008) Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 88:339–347CrossRefPubMed

Title: Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker
Authors: Rajan Jain
Lisa M. Scarpace
Shehanaz Ellika
Roy Torcuator
Lonni R. Schultz
David Hearshen
Tom Mikkelsen
Publication date: 01-02-2010
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2010
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-009-9981-6

At a glance: The STEP trials

Springer Medicine

Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis

Diffusion tensor-based tumor infiltration index cannot discriminate vasogenic edema from tumor-infiltrated edema

Breast cancer brain metastases express the sodium iodide symporter

Directed evolution of adeno-associated virus for glioma cell transduction

In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation

Extended-schedule dose-dense temozolomide in refractory gliomas